Ionis Pharmaceuticals (IONS) News Today → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free IONS Stock Alerts $37.31 -0.31 (-0.82%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 12:12 AM | marketbeat.comNicola Wealth Management LTD. Purchases 26,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Nicola Wealth Management LTD. increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 86.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 56,000 shares of the company's stock afterMay 17 at 1:53 PM | markets.businessinsider.comIonis Pharmaceuticals Buy Rating Affirmed on Strong Clinical Data and Robust Pipeline PotentialMay 17 at 12:52 PM | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest UpdateIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 8,750,000 shares, a decrease of 8.2% from the April 15th total of 9,530,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is presently 8.1 days. Currently, 6.5% of the company's stock are short sold.May 16 at 11:00 PM | marketbeat.comNikko Asset Management Americas Inc. Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Nikko Asset Management Americas Inc. trimmed its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 252,459 shares of the company's stock after selling 40,014 shares durMay 16 at 4:00 PM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Sees Strong Trading VolumeIonis Pharmaceuticals (NASDAQ:IONS) Sees Unusually-High Trading VolumeMay 16 at 12:46 PM | markets.businessinsider.comIonis Reports Positive Topline Data From The HALOS Phase 1/2a Study In Angelman SyndromeMay 16 at 7:41 AM | reuters.comBiogen, Ionis to discontinue development of ALS drugMay 16 at 7:30 AM | prnewswire.comIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 16 at 7:00 AM | prnewswire.comIonis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndromeMay 15 at 5:40 PM | marketbeat.comFirst Turn Management LLC Invests $18.04 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)First Turn Management LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 356,679 shares of the company's stock, vMay 15 at 7:05 AM | prnewswire.comIonis to host 2024 virtual Annual Meeting of StockholdersMay 14, 2024 | marketbeat.comNicholas Investment Partners LP Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Nicholas Investment Partners LP purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 30,445 shares of the company's stoMay 12, 2024 | marketbeat.comJump Financial LLC Reduces Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Jump Financial LLC reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 48.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 61,739 shares of the company's stock after selling 57,661 sharMay 12, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)May 10, 2024 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) PT Lowered to $82.00May 9, 2024 | finance.yahoo.comThe Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 8, 2024 | washingtonpost.comTKO Group: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comThe Analyst Landscape: 8 Takes On Ionis PharmaceuticalsMay 8, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comWells Fargo & Company Trims Ionis Pharmaceuticals (NASDAQ:IONS) Target Price to $82.00Wells Fargo & Company decreased their price objective on Ionis Pharmaceuticals from $85.00 to $82.00 and set an "overweight" rating on the stock in a report on Wednesday.May 8, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPSIonis Pharmaceuticals (NASDAQ:IONS - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.12. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The business had revenue of $119.00 million for the quarter, compared to analysts' expectations of $131.42 million. During the same quarter in the prior year, the business earned ($0.87) EPS. The business's revenue for the quarter was down 9.2% compared to the same quarter last year.May 8, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Wednesday.May 8, 2024 | finance.yahoo.comIonis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...May 8, 2024 | finance.yahoo.comQ1 2024 Ionis Pharmaceuticals Inc Earnings CallMay 8, 2024 | finance.yahoo.comIonis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III Sells 6,000 Shares of StockMay 8, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells $256,260.00 in StockMay 7, 2024 | marketbeat.comJoseph Klein III Sells 6,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Joseph Klein III sold 6,000 shares of the business's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $42.71, for a total value of $256,260.00. Following the completion of the transaction, the director now directly owns 16,346 shares in the company, valued at approximately $698,137.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.May 7, 2024 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis reports first quarter 2024 financial resultsMay 7, 2024 | msn.comIONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | prnewswire.comIonis reports first quarter 2024 financial resultsMay 7, 2024 | marketbeat.comCwm LLC Sells 55,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Cwm LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 96.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,197 shares of the company's stock after selling 55,009 shares during theMay 6, 2024 | marketbeat.comLisanti Capital Growth LLC Purchases Shares of 62,415 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Lisanti Capital Growth LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 62,415 shares of the company's stock, valued aMay 6, 2024 | msn.comIonis Pharmaceuticals Q1 2024 Earnings PreviewMay 2, 2024 | marketbeat.comCalifornia Public Employees Retirement System Has $10.60 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)California Public Employees Retirement System lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 68.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,436 shApril 27, 2024 | marketbeat.comC WorldWide Group Holding A S Acquires New Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)C WorldWide Group Holding A S acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 300,000 shares of the company's stock, valued aApril 26, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 92.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,440 shares of the company's stock after selling 343,899April 25, 2024 | prnewswire.comIonis Publishes 2023 Corporate Responsibility ReportApril 23, 2024 | prnewswire.comIonis to hold first quarter 2024 financial results webcastApril 23, 2024 | marketbeat.com24,779 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Strs OhioStrs Ohio bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 24,779 shares of the company's stock, valued at approximately $1,253,000. Several other institutional iApril 18, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 SharesApril 17, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $166,649.60 in StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the completion of the transaction, the executive vice president now owns 19,631 shares in the company, valued at $816,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.April 17, 2024 | marketbeat.comFY2026 EPS Estimates for Ionis Pharmaceuticals, Inc. Lifted by Leerink Partnrs (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Analysts at Leerink Partnrs raised their FY2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued on Tuesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company willApril 16, 2024 | marketbeat.com24,243 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by HealthInvest Partners ABHealthInvest Partners AB purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 24,243 shares of the company's stock, valued at approximatelApril 15, 2024 | nasdaq.comIONS Quantitative Stock AnalysisApril 14, 2024 | marketbeat.comGranite Bay Wealth Management LLC Sells 34,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Granite Bay Wealth Management LLC reduced its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 71.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,579 shares of the company's stock afterApril 12, 2024 | msn.comWolfe upgrades Ionis to outperform, cites upcoming catalystsApril 11, 2024 | investing.comIonis Pharmaceuticals stock upgraded to OutperformApril 11, 2024 | investing.comIonis Pharmaceuticals stock upgraded to OutperformApril 10, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Lifted to Outperform at Wolfe ResearchWolfe Research upgraded Ionis Pharmaceuticals from a "peer perform" rating to an "outperform" rating in a report on Wednesday. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 IONS Media Mentions By Week IONS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.690.50▲Average Medical News Sentiment IONS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼135▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MDGL News Today ALKS News Today FOLD News Today BHC News Today ACAD News Today GERN News Today LGND News Today DVAX News Today UTHR News Today BMRN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
